If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- Staying ahead in the era of precision medicineon March 20, 2020 at 2:48 am
But what are the barriers? The challenges around precision medicine are illustrated perfectly by looking at lung cancer as an example: treatments such as chemotherapy and radiation were once fairly ...
- New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapyon March 19, 2020 at 10:05 pm
March 19, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery ... it provides evidence that patients who have previously received immune ...
- A New Star in Treatment to Fight Canceron March 19, 2020 at 5:35 pm
ITRI’s work in the development of precision medicine has again garnered international accolades. After winning a 2019 R&D 100 Award, ITRI’s iKNOBEADS, the world’s only biomimetic knobby magnetic beads ...
- Global Virtual Knowledgebase and Novel Coronavirus Expert Network to Support Cancer Communityon March 18, 2020 at 4:14 am
pandemic, GRYT Health, ("grit") creator of the Global Virtual Cancer Conference and the GRYT Health Cancer Platform, has partnered with the American Association of Precision Medicine (AAPM), a ...
- NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Canceron March 18, 2020 at 4:05 am
SALT LAKE CITY, March 18, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced that the National Comprehensive ...
- FHIR Genomics: enabling standardization for precision medicine use caseson March 18, 2020 at 3:11 am
The development of Fast Healthcare Interoperability Resources (FHIR) Genomics, a feasible and efficient method for exchanging complex clinical genomic data and interpretations, is described. FHIR ...
- New Approaches for the Treatment of Clear Cell Carcinomaon March 17, 2020 at 2:42 pm
Treatment typically consists of surgery to remove as much of the cancer as possible, followed by systemic chemotherapy, interleukin-2 or targeted therapy with Sutent (sunitinib) MK-6482 is a novel ...
- Analysis Yields Potential New Precision Medicine Path in mHSPCon March 16, 2020 at 7:58 pm
A correlative study of gene expression profiling data from the phase III CHAARTED trial identified varying benefits with different treatment approaches in patients with different subtypes of ...
- The multidisciplinary management of rectal canceron March 12, 2020 at 10:34 am
Rectal cancer treatment has evolved towards a multidisciplinary approach to disease management. This Review examines the essential components of rectal cancer management through a multidisciplinary ...
via Bing News